October 7, 2025 — Leads & Copy — Dogwood Therapeutics, Inc. (Nasdaq:DWTX), a development-stage biotechnology company, announced its Chief Medical Officer will present an overview of the Halneuron®(tetrodotoxin) pain management research program at the 19th Annual Pain Therapeutics Summit on October 14, 2025.
Dogwood Therapeutics is developing Halneuron®, a highly purified version of tetrodotoxin, to treat Chemotherapy Induced Neuropathic Pain (“CINP”). Tetrodotoxin (“TTX”) is a potent and specific modulator of the Nav 1.7 sodium channel. Current research suggests that the Nav 1.7 channel is a key regulator of the threshold for depolarization of sensory neurons, whereas changes in Nav 1.8 regulate the rate of repolarization of sensory neurons.
A recently conducted pre-clinical study compared the efficacy of Halneuron (Nav 1.7 modulator) and VX-548 (Nav 1.8 modulator) in rats with CINP and investigated the potential additive efficacy of combining the two agents. Halneuron® and VX-548 rapidly and significantly suppressed mechanical allodynia in this preclinical CINP model, with Halneuron® demonstrating pain reduction comparable to or greater than VX-548. Notably, the combination did not show additive synergy in reducing pain in the rat model.
To date, over 700 patients have been treated in human clinical studies with TTX for a variety of potential indications. Halneuron® has demonstrated pain reduction in general cancer related pain in a large multicenter Phase 2 study, as well as in a subsequent Phase 2 CINP study. Halneuron® is currently being evaluated in a Phase 2b clinical trial (HALT-CINP) being conducted at 25 sites in the United States. The goal of this study is to assess the safety and efficacy of low dose injectable Halneuron® in reducing long standing CINP in cancer patients.
Dogwood is also developing SP16 IV, an LRP1 agonist with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. The forthcoming SP16 IV Phase 1b CINP trial, which has been fully funded by the National Cancer Institute, is projected to commence enrolling patients in the first half of 2026.
Investor Relations: CORE IR, (516) 222-2560, IR@dwtx.com
Source: Dogwood Therapeutics, Inc.
